TP-110, a new proteasome inhibitor, down-regulates IAPs in human multiple myeloma cells

Anticancer Research

Volumn 29, Issue 4, 2009, Pages 977-986

  Iijima, Masatom ^a   Momose, Isao ^a   Ikeda, Daishiro ^a  

^a Numazu Bio Medical Research Institute   (Japan)

Author keywords

Apoptosis; IAP; Multiple myeloma; Proteasome inhibitor; TP 110

Indexed keywords

APOPTOSIS REGULATORY PROTEIN; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; CASPASE 3; CASPASE 8; CASPASE 9; CYTOCHROME C; FAS ANTIGEN; INHIBITOR OF APOPTOSIS PROTEIN 1; PROTEASOME INHIBITOR; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN BID; TP 110; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; HUMAN; HUMAN CELL; LEUKEMIA CELL; MULTIPLE MYELOMA; MYELOMA CELL; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN SECRETION; SENSITIZATION;

APOPTOSIS; CASPASES; CYTOCHROMES C; DOWN-REGULATION; HUMANS; IMMUNOBLOTTING; INHIBITOR OF APOPTOSIS PROTEINS; MULTIPLE MYELOMA; OLIGOPEPTIDES; POLY(ADP-RIBOSE) POLYMERASES; PROTEASOME ENDOPEPTIDASE COMPLEX; TUMOR CELLS, CULTURED;

EID: 64949101030     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Adams J: The proteasome:a suitable antineoplastic target. Nature Review Cancer 4: 349-360, 2004.
2. Maki CG and Howley PM: Ubiqitination of p53 and p21 is differentially affected by ionizing and UV radiation. Mol Cell Bio 17: 355-363, 1997.
3. Pagano M, Tam SW, Theodoras AM, Beerromero P, Sal GD, Chau V, Yew PR, Draetta GF and Rolfe M: Role of the ubiquitin- proteasome pathway in regulating abundance of the cyclin- dependent kinase inhibitor p27. Science 269: 682-685, 1995.
4. Deveraux QL, Takahashi R, Salvesen GS and Reed JC: X-linked IAP is a direct inhibitor of cell-death proteases. Nature 388: 300- 304, 1997.
5. Paopmbella VJ, Rando OJ, Goldberg AL and Maniatis T: The ubiquitin-proteasmome pathway is required for processing the NF-κB1 precursor protein and the activation of NF-κB. Cell 78: 773-785, 1994.
6. Momose I, Sekizawa R, Hirosawa S, Ikeda D, Naganawa H, Iinuma H and Takeuchi T: Tyropeptin A and B, new proteasome inhibitors produced by Kitasatospora sp. MK993-dF2. II. Structure determination and synthesis. J Antibiotics 54: 1004- 1012,2001.
7. Momose I, Sekizawa R, Iinuma H and Takeuchi T: Inhibition of proteasome activity by tyropeptin A in PC-12 cells. Biosci Biotecnol Biochem 66: 2256-2258, 2002.
8. Momose I, Umezawa Y, Hirosawa, Iinuma H and Ikeda D: Structure-based design of derivatives of tyropeptin A as the potent and selective inhibitors of mammalian 20S proteasome. Bioorg Med Chem Lett 15: 1867-1871, 2005.
9. Momose I, Umezawa Y, Hirosawa S, Iijima M, Iinuma H and Ikeda D: Synthesis and activity of tyropeptin A derivatives as potent and selective inhibitors of mammalian 20S proteasome. Biosci Biotechnol Biochem 69: 1733-1742, 2005.
10. Momose I, Iijima M, Kawada M and Ikeda D: A new proteasome inhibitor TP-110 induces apoptosis in human prostate cancer PC-3 cells. Biosci Biotechnol Biochem 71: 1036-1043, 2007.
11. Fesik SW: Promoting apoptosis as a strategy for cancer drug discovery. Nature Review Cancer 5: 876-885, 2005.
12. Hanahan D and Weinberg RA: The hallmarks of cancer. Cell 100: 57-70, 2000.
13. Uzzo RG, Haas NB, Crispen PL and Kolenko VM: Mechanisms of apoptosis resistance and treatment strategies to overcome them in hormone-refractory prostate cancer. Cancer 112: 1660-1671, 2008.
14. Kim TH, Zhao Y, Barber MJ, Kuharsky DK and Yin XM: Bid- induced cytochrome c release is mediated by a pathway independent of mitochondrial permeability transition pore and Bax. J Biol Chem 275: 39474-39481, 2000.
15. Scott FL, Denault JB, Riedl SJ, Shin H, Renatus M and Salvesen GS: XIAP inhibits caspase-3 and -7 using two binding sites: evolutionarily conserved mechanism of IAP. EMBO J 24: 645- 655, 2005.
16. Schimmer AD, Dalili S and Riedl SJ: Targeting XIAP for the treatment of malignancy. Cell Death and Differentiation 13: 179- 188, 2006.
17. Enari M, Sakahira H, Yokoyama H, Okawa K, Iwamatsu A and Nagata S: A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD. Nature 391: 43-50, 1998.
18. Gross A, McDonnell JM and Korsmeyer SJ: BCL-2 family members and the mitochondria in apoptosis. Genes Dev 13: 1899-1911, 1999.
19. Grinberg M, Sarig R, Zaltsman Y, Frumkin D, Grammatikakis N, Reuveny E and Gross A: tBID Homooligomerizes in the mitochondrial membrane to induce apoptosis. J Biol Chem 277: 12237-12245, 2002.
20. Deveraux QL and Reed JC: IAP family proteins suppressors of apoptosis. Genes Dev 13: 239-252, 1999.
21. Elliott PJ, Zollner TM and Boehncke WH: Proteasome inhibition: a new anti-inflammatory strategy. J Mol Med 81: 235-245, 2003.
22. Almond JB, Snowden RT, Hunter A, Dinsdale D, Cain KJM, Dumont J, Binet JL and Magdelenet H: The proteasome: a novel target for cancer chemotherapy. Leukemia 16: 433-443, 2002.
23. Adams J, Behnke M, Chen S, Cruickshank AA, Dick LR, Grenier L, Klunder JM, Ma YT, Plamondon L and Stein RL: Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids. Bioorg Med Chem Lett 8: 333-338, 1998.
24. Orlowski RZ and Kuhn DJ: Proteasome inhibitors in cancer therapy: lessons from the first decade. Clin Cancer Res 14: 1649-1657, 2008.
25. Chauhan D, Hideshima T and Anderson KC: Proteasome inhibition in multiple myeloma: therapeutic implication. Annu Rev Pharmacol Toxicol 45: 465-476, 2005.
26. Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J and Anderson KC: The proteasome inhibitor PS- 341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 61: 3071-3076, 2001.
27. Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Richardson PG, Hideshima T, Munshi N, Treon SP and Anderson KC: Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications. Blood 99: 4079- 4086, 2002.
28. Hideshima T, Chauhan D, Richardson P, Mitsiades C, Mitsiades N, Hayashi T, Munshi N, Dang L, Castro A, Palombella V, Adams J and Anderson KC: NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem 277: 16639-16647, 2002.
29. Ashkenazi A: Targeting death and decoy receptors of the tumor- necrosis factor superfamily. Nat Rev Cancer 2: 420-430, 2002.
30. Deveraux QL, Takahashi R, Salvesen GS and Reed JC: X-linked IAP is a direct inhibitor of cell-death proteases. Nature 388: 300- 304, 1997.
31. Momand J, Wu HH and Dasgupta G: MDM2 master regulator of the p53 tumor suppressor protein. Gene 242: 15-29, 2000.
32. Ezekwudo D, Shashidharamurthy R, Devineni D, Bozeman E, Palaniappan R and Selvaraj P: Inhibition of expression of antiapoptotic protein Bcl-2 and induction of cell death in radioresistant human prostate adenocarcinoma cell line (PC-3) by methyl jasmonate. Cancer Lett 270: 277-285, 2008.
33. Schimmer AD, Welsh K, Pinilla C, Wang Z, Krajewska M, Bonneau MJ, Pedersen IM, Kitada S, Scott FL, Bailly-Maitre B, Glinsky G, Scudiero D, Sausville E, Salvesen G, Nefzi A, Ostresh JM, Houghten RA and Reed JC: Small-molecule antagonists of apoptosis suppressor XIAP exhibit broad antitumor activity. Cancer Cell 5: 25-35, 2004.
34. Wang CY, Mayo MW, Korneluk RG, Goeddel DV and Baldwin AS Jr: NF-κB antiapoptosis: induction of TRAF1 and TRAF2 and cIAP-1 and cIAP-2 to suppress caspase-8 activation. Science 281: 1680-1683, 1998.
35. Kashkar H, Deggerich A, Seeger JM, Yazdanpanah B, Wiegmann K, Haubert D, Pongratz C and Kronke M: NF-kappa;B-independent down-regulation of XIAP by bortezomib sensitizes HL B cells against cytotoxic drugs. Blood 109: 3982-3988, 2007.
36. Cheung HH, LaCasse EC and Korneluk RG: X-linked inhibitor of apoptosis antagonism: strategies in cancer treatment. Clin Cancer Res 12: 3238-3242, 2006.
37. Jin Z, McDonald ER 3rd, Dicker DT and El-Deiry WS: Deficient tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor transport to the cell surface in human colon cancer cells selected for resistance to TRAIL-induced apoptosis. J Biol Chem 279: 35829-35839, 2004.
38. Kazhdan I and Marciniak RA: Death receptor 4 (DR4) efficiently kills breast cancer cells irrespective of their sensitivity to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Cancer Gene Ther 11: 691-698, 2004.
39. Leverkus M, Sprick MR, Wachter T, Mengling T, Baumann B, Serfling E, Brocker EB, Goebeler M, Neumann M and Walczak H: Proteasome inhibition results in TRAIL sensitization of primary keratinocytes by removing the resistance-mediating block of effector caspase maturation. Mol Cell Biol 23: 777-790, 2003.
40. Varfolomeev E, Goncharov T, Fedorova AV, Dynek JN, Zobel K, Deshayes K, Fairbrother WJ and Vucic D: c-IAPl and C-IAP2 are critical mediators of tumor necrosis factor alpha (TNFalpha)-induced NF-kappaB activation. J Biol Chem 283: 24295-24299, 2008.
41. Li L, Thomas RM, Suzuki H, De Brabander JK, Wang X and Harran PG: A small molecule Smac/DIABLO mimic potentiates TRAIL- and TNFa-mediated cell death. Science 305: 1471- 1474, 2004.
42. Deng Y, Lin Y and Wu X: TRAIL-induced apoptosis requires Bax-dependent mitochondrial release of Smac/DIABLO. Genes Dev 16: 33-45, 2002.